Better Therapeutics, Inc.
Healthcare · Services-Health Services · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | |
|---|---|---|---|
| Revenue | — | — | $8,000 |
| Operating income | −$38.3M | −$30.6M | −$6.3M |
| Net income | −$39.8M | −$40.3M | −$1,686 |
| Total assets | $22.9M | $51.0M | $86,658 |
| Total liabilities | $23.8M | $14.2M | $63,344 |
| Equity | −$899,000 | $36.7M | $23,314 |
| EPS (diluted) | $-1.69 | $-3.11 | — |
| Shares out. | 23.6M | 7.6M | 1.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- 4422.7%
- Return on assets
- −173.3%
- Return on capital (ROCE)
- −404.9%
- Liabilities / assets
- 103.9%
- Debt / equity
- —
- Book value / share
- $-0.04
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -25.67distress
- Accruals / assets
- −47.2%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 15, 2021
- NT 10-Qmissed a reporting deadline ↗Aug 17, 2021
- NT 10-Qmissed a reporting deadline ↗May 17, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Debt acceleration / triggering eventMar 21, 2024
- Delisting / listing-standard notice · Director / officer changeMar 15, 2024
- Delisting / listing-standard notice · Other material eventMar 14, 2024
- Regulation FD disclosureMar 11, 2024
- Regulation FD disclosureMar 4, 2024
- Entered a material agreement · Results of operations · Unregistered equity saleJan 8, 2024
- Delisting / listing-standard noticeDec 18, 2023
- Entered a material agreementDec 13, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.